CCL5 and infection: Despite the protective role of Met-CCL5 in the early days of infection, over 50% of Met-CCL5 treated adult mice still died after 19 days p.i. (Figure 6C), suggesting that additional treatment might be combined with Met-CCL5 to improve anti-RABV efficacy.